stockrowDianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
Follow DNTH
Alert me
Dianthus Therapeutics, Inc. (DNTH) EBITDA
Dianthus Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$183.7M, compared with −$107.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$244.2M. Over the past ten years it has ranged from −$183.7M (fiscal 2025) to −$9.3M (fiscal 2016) — the current reading is the lowest in ten years. EBITDA has fallen for 3 consecutive fiscal years. Dianthus Therapeutics, Inc. ranks 532nd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$183.7M | — |
| FY2024 | −$107.5M | — |
| FY2023 | −$49.2M | — |
| FY2022 | −$30.2M | — |
| FY2021 | −$72.7M | — |
| FY2020 | −$76.7M | — |
| FY2019 | −$81.1M | — |
| FY2018 | −$59.1M | — |
| FY2017 | −$35.4M | — |
| FY2016 | −$9.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$59.2M | — |
| Jun 2026 | −$67.0M | — |
| Mar 2026 | −$47.7M | — |
| Dec 2025 | −$70.3M | — |
| 33 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$19.0M |
| TVTX Travere Therapeutics, Inc. compare | −$83.5M |
| MANE Veradermics Incorporated compare | −$88.4M |
| EWTX Edgewise Therapeutics, Inc. compare | −$221.9M |
| DFTX Definium Therapeutics, Inc. compare | −$227.7M |
| DNTH Dianthus Therapeutics, Inc. | −$244.2M |
| ERAS Erasca, Inc. compare | −$302.6M |
| COGT Cogent Biosciences, Inc. compare | −$388.7M |
| CRSP CRISPR Therapeutics AG compare | −$513.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on DNTH
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement